Skip to content
Open access

Cryo-EM Structures of Infectious Low-Twist α-Synuclein Filaments in Lewy Bodies

Sep 2026 · bioRxiv · 0 citations · 8 references
Medicine Biology

TL;DR

It is established that low-twist filaments, which include over 75% of disease-associated Lewy aSyn amyloids, share a common structural core with high-twist forms and are the predominant aSyn species in samples that engage in templated infection.

Abstract

α-Synuclein (aSyn) aggregation within Lewy bodies underlies Parkinson’s disease and associated dementias. These aggregates are often comprised of amyloid filaments, most of which appear untwisted or have extremely low twist, complicating high-resolution structural determination by cryogenic electron microscopy (cryo-EM). Here, we isolated filaments from the brain tissue of a patient with dementia with Lewy bodies and show infectivity in a cell line system that propagates Lewy aSyn. Then, we determined 2.3–2.9 Å cryo-EM structures of low-twist aSyn filaments from this tissue and from a publicly available Parkinson’s disease dementia dataset. In both structures, the protofilament adopts a fold highly similar to the canonical Lewy fold with conserved cofactor and peptidic densities. Compared to previously resolved high-twist filaments, the low-twist filament is left-handed and flattened along the filament axis, resulting in register shifts of interlayer contacts, while preserving the overall architecture. Our results establish that low-twist filaments, which include over 75% of disease-associated Lewy aSyn amyloids, share a common structural core with high-twist forms and are the predominant aSyn species in samples that engage in templated infection.

Read PDF

Similar papers

Open access Sep 2026

Cryo-ET and Sub-Volume Analysis of Fibrillar Pathology in the Neurodegenerative Human Brain

Combined with existing high-resolution fibril structures lacking spatial context, cryo-ET offers a powerful approach to understanding amyloid polymorphism in neurodegenerative diseases, advancing anti-amyloid therapies and diagnostic tools.

Lukas van den Heuvel, Daniel A. Stähli, Julika Radecke et al. · 0 citations
Aug 2026

Structural basis of α-synuclein and DJ-1 complex.

Based on the structure, a DJ-1-derived peptide (173-180) is designed that significantly inhibited α-synuclein aggregation in TEM and ELISA assays, suggesting its potential as a therapeutic candidate for α-synucleinopathies.

Hyeon Jin Kim, Da Hye Kim, Chang-Woo Han et al. · 0 citations
Open access Aug 2026

Differently sized soluble α-synuclein species from multiple system atrophy and Lewy body disease brains display different seeding propensities

Different conformations, or strains, of α-synuclein (α-syn) aggregates are believed to be responsible for the distinct seeding propensities, propagation profiles, and clinical presentations in Lewy body diseases (LBD) and multiple system atrophy (MSA). While biochemical properties and strain differences of insoluble de...

S. Zampar, Y. Mei, F. Samuel et al. · 0 citations
Open access

Aggregation, Propagation and Pathological Implications of α-synuclein Amyloid Fibrils in Parkinson’s Disease

It is shown that α-synuclein fibrils are more structurally heterogenous than previously believed and that they may continue to remodel their architecture over the course of PD, and fibril assembly pathways and resulting fibril structure are highlighted as critical targets for future therapeutic strategies.

Fritjof Havemeister · 0 citations
Open access Aug 2026

Multiple system atrophy-derived α-synuclein fibrils are more potent and display oligodendrocyte cell tropism compared to Parkinson's disease-derived fibrils.

Interestingly, amplified material from MSA brains induced significantly more oligodendroglial pSyn aggregates than amplified material from PD brains, and mice injected with the fibril polymorph, showed mild changes in microglial reactivity.

Anne-Line Strange Laursen, K. Willén, Alexis Fenyi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.